Kin Lok Ho

Kin Lok Ho is a Development Chemist at Sterling Pharma Solutions since February 2023, with prior experience as a Radiosynthetic Chemist at Quotient Sciences from January 2022 to February 2023. Kin Lok Ho served as a Research Associate in Dr. Michael Hall's research group at Newcastle University from May 2020 to January 2022, focusing on semi-synthetic modifications of rifamycin and kanglemycin A to develop new antibiotics against multidrug-resistant bacteria. Kin Lok Ho completed a Doctor of Philosophy in Organic Chemistry at Newcastle University in 2020 and earned a Bachelor of Science in Chemistry from the same institution in 2016.